The results of new low dose fractional CO2 Laser – A prospective clinical study in France - 23/02/20
pages | 6 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objectives |
The aim of this research was to assess the efficacy of the new generation micro-fractional CO2 laser low dose energy (Aphrodite, BH LASER, France) in the treatment of genitourinary syndrome.
Materials and Methods |
This prospective interventional clinical study, included a total of 25 menopausal symptomatic patients and 25 non-menopausal symptomatic patients having symptoms of vulvovaginal atrophy. There were only two laser sessions spaced at 6 weeks.
It was evaluated the Female Sexual Function Index (FSFI) and the QoL at baseline, 3 and 6 months.
Results |
The study showed a significant improvement in both groups when assessing FSFI scores at 3- and 6-months follow-up compared to baseline (p<0.05) and secondary it was observed a significant initial improvement of QoL score at 3 and 6 months (p<0.05), compared to baseline.
There were no important adverse events registered during the study period.
Conclusions |
The new micro-fractionated laser device with low dose energy – 18W, demonstrated significant improvement of genitourinary syndrome in both non-menopausal and post-menopausal women with no important adverse event.
Le texte complet de cet article est disponible en PDF.Keywords : Micro-fractional CO2 laser, Genito-urinary syndrome, Menopause, Vaginal atrophy, Dyspareunia
Plan
Vol 49 - N° 3
Article 101614- mars 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?